Transitions Optical Archives - Page 2 of 21

Transitions Unveils Updated Website Exclusively for Canadian Eyecare Professionals

Tuesday, September 3 2024 | 16 h 09 min | News

Transitions Optical has launched an updated website designed exclusively for Canadian eyecare professionals—with access to educational tools and...

Transitions Optical Offers New Transitions® GEN S™ Training Program

Wednesday, August 21 2024 | 07 h 12 min | News

Transitions Optical, in collaboration with the Opticians Association of Canada (OAC), is launching a new Transitions GEN S certification program...

Transitions® Showcases Gen S at Festival d’été de Quebec

Monday, July 22 2024 | 08 h 10 min | News

Transitions® showcased Gen STM at the Festival d'été de Québec from July 4 to July 14 Located on Grande Allée, the booth featured an...

Nikon Optical Canada Launches Transitions® GEN S™ – Pushing Innovation Even Further

Tuesday, April 9 2024 | 08 h 03 min | News

Nikon Optical Canada introduces Transitions® GEN S™ the latest innovation on the market to provide eyeglass lens wearers more than just...

Transitions Unveils Finalists for the 2023 Transitions® Innovation Awards

Tuesday, January 23 2024 | 09 h 44 min | News

Transitions Optical has named the finalists for its annual Transitions® Innovation Awards program, which honors both individuals and organizations...

« Previous 1 2 3 4 … 21 Next »

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. logos

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Tag: Transitions Optical

Transitions Unveils Updated Website Exclusively for Canadian Eyecare Professionals

Transitions Optical Offers New Transitions® GEN S™ Training Program

Transitions® Showcases Gen S at Festival d’été de Quebec

Nikon Optical Canada Launches Transitions® GEN S™ – Pushing Innovation Even Further

Transitions Unveils Finalists for the 2023 Transitions® Innovation Awards

Featured Posts

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement